These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 9269289)
21. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L; Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171 [TBL] [Abstract][Full Text] [Related]
22. Progress in timely vaccination coverage among children living in low-income households. Smith PJ; Jain N; Stevenson J; Männikkö N; Molinari NA Arch Pediatr Adolesc Med; 2009 May; 163(5):462-8. PubMed ID: 19414693 [TBL] [Abstract][Full Text] [Related]
23. Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants. Chotpitayasunondh T; Panpitpat C; Thisyakorn U; Furer E; Que JU; Hasler T; Cryz SJ Southeast Asian J Trop Med Public Health; 1997 Mar; 28(1):91-8. PubMed ID: 9322290 [TBL] [Abstract][Full Text] [Related]
24. Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15-20-month-old toddlers. Halperin SA; Tapiero B; Law B; Diaz-Mitoma F; Duval B; Langley JM; Elrick DB; Jacquet JM Vaccine; 2006 May; 24(18):4017-23. PubMed ID: 16516357 [TBL] [Abstract][Full Text] [Related]
25. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511 [TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine. Cheng HK; Rajadurai VS; Amin Z; Sriram B; Yee MF; Han HH; Bock HL; Safary A Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):685-92. PubMed ID: 15689088 [TBL] [Abstract][Full Text] [Related]
27. Study of adverse events following immunisation with universal and newer vaccines in the Serampore IMA Child Clinic over a period of 7 years. Das PK J Indian Med Assoc; 2013 Apr; 111(4):230, 232-4. PubMed ID: 24475552 [TBL] [Abstract][Full Text] [Related]
28. Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine. Panpitpat C; Thisyakorn U; Chotpitayasunondh T; Fürer E; Que JU; Hasler T; Cryz SJ Bull World Health Organ; 2000; 78(3):364-71. PubMed ID: 10812736 [TBL] [Abstract][Full Text] [Related]
29. Inactivated influenza vaccine (IIV) in children <2 years of age: examination of selected adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) after thimerosal-free or thimerosal-containing vaccine. McMahon AW; Iskander JK; Haber P; Braun MM; Ball R Vaccine; 2008 Jan; 26(3):427-9. PubMed ID: 18093701 [TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age. Halperin SA; Tapiero B; Diaz-Mitoma F; Law BJ; Hoffenbach A; Zappacosta PS; Radley D; McCarson BJ; Martin JC; Brackett LE; Boslego JW; Hesley TM; Bhuyan PK; Silber JL Vaccine; 2009 Apr; 27(19):2540-7. PubMed ID: 19124057 [TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conjugate vaccine in infants aged 12-18 months. Usonis V; Meriste S; Bakasenas V; Lutsar I; Collard F; Stoffel M; Tornieporth N Vaccine; 2005 Apr; 23(20):2602-6. PubMed ID: 15780442 [TBL] [Abstract][Full Text] [Related]
32. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group. Schmitt-Grohé S; Stehr K; Cherry JD; Heininger U; Uberall MA; Laussucq S; Eckhardt T Dev Biol Stand; 1997; 89():113-8. PubMed ID: 9272341 [TBL] [Abstract][Full Text] [Related]
33. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine. Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366 [TBL] [Abstract][Full Text] [Related]
34. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus- inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. Schmitt HJ; Knuf M; Ortiz E; Sänger R; Uwamwezi MC; Kaufhold A J Pediatr; 2000 Sep; 137(3):304-12. PubMed ID: 10969252 [TBL] [Abstract][Full Text] [Related]
35. How do physicians immunize their own children? Differences among pediatricians and nonpediatricians. Posfay-Barbe KM; Heininger U; Aebi C; Desgrandchamps D; Vaudaux B; Siegrist CA Pediatrics; 2005 Nov; 116(5):e623-33. PubMed ID: 16263976 [TBL] [Abstract][Full Text] [Related]
36. Surveillance of adverse events following immunisation: Australia, 2000-2002. Lawrence G; Menzies R; Burgess M; McIntyre P; Wood N; Boyd I; Purcell P; Isaacs D Commun Dis Intell Q Rep; 2003; 27(3):307-23. PubMed ID: 14510057 [TBL] [Abstract][Full Text] [Related]
37. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vellozzi C; Burwen DR; Dobardzic A; Ball R; Walton K; Haber P Vaccine; 2009 Mar; 27(15):2114-20. PubMed ID: 19356614 [TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine. Black SB; Cimino CO; Hansen J; Lewis E; Ray P; Corsaro B; Graepel J; Laufer D Pediatr Infect Dis J; 2006 Apr; 25(4):306-11. PubMed ID: 16567981 [TBL] [Abstract][Full Text] [Related]
39. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants. Lin TY; Wang YH; Chang LY; Huang YC; Kao HT; Lin PY; Lu HK; Chavand P; Ortiz E Int J Infect Dis; 2007 Mar; 11(2):129-36. PubMed ID: 16762579 [TBL] [Abstract][Full Text] [Related]
40. Disease-specific adverse events following nonlive vaccines: a paradoxical placebo effect or a nocebo phenomenon? Okaïs C; Gay C; Seon F; Buchaille L; Chary E; Soubeyrand B Vaccine; 2011 Aug; 29(37):6321-6. PubMed ID: 21627976 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]